Doxorubicin (hydrochloride) [25316-40-9]

Catalog number: HY-15142_100mg
Brand: MedChem Express
Packing: 100 mg
Other sizes: 50 mg
10 mM
200 mg
500 mg
1 g
Price: € 115.00
Expected delivery time: 10 days
Quantity:
Doxorubicin hydrochloride Chemical Structure
CAS No. : 25316-40-9...

Product specifications for - Doxorubicin (hydrochloride) [25316-40-9]

Overview: 
Product group: Chemicals
Category: Other
CAS No.: 25316-40-9
Properties: 
Purity: >98%
Molecular Formula: C27H30ClNO11
Molecular weight: 579.98
Datasheet: Datasheet
  Research Use Only
UNSPSC: 12352200
Scientific information: 
Scientific info: Doxorubicin Hcl(Adriamycin) is an antibiotic agent that inhibits DNA topoisomerase II and induces DNA damage and apoptosis. IC50 Value: Target: Topo II, ADCs Toxin in vitro: Doxorubicin can block the synthesis of DNA by intercalating into the DNA strand, and inhibits DNA topoisomerase II (TOP2). Doxorubicin is most effective when cells are rapidly proliferating and expressing high levels of TOP2. Additionally, Doxorubicin can trigger apoptosis by producing ceramide (which prompts apoptosis by activating p53 or other downstream pathways such as JNK), the degradation of Akt by serine threonine proteases, the mitochondrial release of cytochrome c, increased FasL (death receptor Fas/CD95 ligand) mRNA production, and a greater production of free radicals. Doxorubicin induced G2/M checkpoint arrest are attributed to elevated cyclin G2 (CycG2) expression and phospho-modification of proteins in the ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) signaling pathways. Doxorubicin inhibits AMP-activated protein kinase (AMPK), resulting in SIRT1 dysfunction, p53 accumulation, and increased cell death in mouse embryonic fibroblasts (MEFs) and cardiomyocytes, which can be further sensitized by pre-inhibition of AMPK. in vivo: Doxorubicin in combination with adenoviral MnSOD (AdMnSOD) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) has the greatest effect in decreasing the volumes of MB231 tumors and prolonging survival of mice. Although its use is limited by the chronic and acute toxic side effects it produces, Doxorubicin is essential in treating breast and oesophageal carcinomas, solid tumours in childhood, osteosarcomas, Kaposi's sarcoma, soft tissue sarcomas, and Hodgkin and non-Hodgkin lymphomas.
Safety information: 
MSDS: MSDS
Additional information: 
Synonyms: HY-15142; Hydroxydaunorubicin hydrochloride; MedChem Express
Burridge PW, Li YF, Matsa E, et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat Med. 2016;22(5):547-56. Read more
Chee YC, Pahnke J, Bunte R, Adsool VA, Madan B, Virshup DM. Intrinsic Xenobiotic Resistance of the Intestinal Stem Cell Niche. Dev Cell. 2018;46(6):681-695.e5. Read more
Guo L, Zhang Y, Wei R, Zhang X, Wang C, Feng M. Proinflammatory macrophage-derived microvesicles exhibit tumor tropism dependent on CCL2/CCR2 signaling axis and promote drug delivery SNARE-mediated membrane fusion. Theranostics. 2020;10(15):6581-6598. Read more
Liu M, Zeng T, Zhang X, et al. ATR/Chk1 signaling induces autophagy through sumoylated RhoB-mediated lysosomal translocation of TSC2 after DNA damage. Nat Commun. 2018;9(1):4139. Read more
Liu Y, Bi X, Xiong J, et al. MicroRNA-34a Promotes Renal Fibrosis by Downregulation of Klotho in Tubular Epithelial Cells. Mol Ther. 2019;27(5):1051-1065. Read more
Lakkadwala S, Dos santos rodrigues B, Sun C, Singh J. Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma. J Control Release. 2019;307:247-260. Read more